Clinical trials: Glabellar Frown Lines
Glabellar Frown Lines
Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®
This study evaluates the long-term safety and efficacy of CORETOX in the treatment of moderate to severe glabellar lines.
- Trial name
- NCT04281745
- Testing
- CORETOX Inj
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Medy-Tox
Frown Lines
Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines
The purpose of the study is to provide preliminary comparative data on BoNT/A-DP versus Botox Cosmetic. Subsequently the sample size is primarily based on clinical judgement and practical considerations.
- Trial name
- H2H (NCT04763265)
- Testing
- Botulinum toxin A "BoNT/A-DP", Botulinum toxin A "Botox Cosmetics"
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 208 people
- Sponsor
- Croma-Pharma GmbH
Glabellar Frown Lines
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines
- Trial name
- NCT05146999
- Testing
- QM1114-DP
- Where
- 9 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Healthy
Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines
NT 201 is a Botulinum toxin type A preparation free of complexing proteins. Injected into the muscle, NT 201 causes a reversible local relaxation of the injected muscle.
- Trial name
- NCT00694148
- Testing
- NT 201
- Where
- Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Frown Lines
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
- Trial name
- NCT03960957
- Testing
- AbobotulinumtoxinA
- Where
- 11 sites in United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines, Rhytides
Split-face Study: Cosmetic Botulinum Toxin Type A Injection Under Electromyography-guidance Versus Conventional Palpation Technique
The aim of this study was to compare between the conventional palpation method of botulinum toxin type A injection and the electromyography-guided method using clinical parameters and electromyography analysis.
- Conditions
- Glabellar Frown Lines, Rhytides, Wrinkle, Facial Expression
- Trial name
- NCT05517538
- Testing
- Electromyography-Needle Intramuscular Drug guidance, Botulinum toxin type A
- Where
- Egypt
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Mohamed Hayder Oleish Salih
Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face
Longitudinal Evaluation and Real-world Evidence of NT201
This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A…
- Trial name
- NCT05222607
- Testing
- IncobotulinumtoxinA
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Merz North America, Inc.
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
The purpose of this study is to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face (Upper Facial…
- Trial name
- ULTRA I (NCT04594213)
- Testing
- NT 201
- Where
- 12 sites in United States
- Volunteers
- 362 people
- Sponsor
- Merz North America, Inc.
Glabellar Frown Lines
The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines
This study will be conducted in Phase I/II clinical trials. In Phase I, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at…
- Trial name
- NCT04996810
- Testing
- PROTOXIN, Botox®
- Where
- 2 sites in South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Glabellar Frown Lines
A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines
Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Botox for a total of 12 weeks after the administration in treatment of glabellar frown lines.
- Trial name
- NCT04281095
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- ATGC Co., Ltd.
Frown Lines
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)
This is a phase 2a, multicenter, open-label, dose-escalation study to evaluate treatment of moderate or severe dynamic forehead lines (FHL) (frontalis) in conjunction with treatment of the glabellar complex.
- Trial name
- NCT03786770
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 4 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Frown Lines
The Treatment of Glabellar Frown Lines
The purpose of this study is to show that two FDA-approved botulinum toxin drugs called Xeomin® and Botox® can reduce the severity of vertical lines (wrinkles) that appear between the eyebrows (glabellar frown lines).
- Trial name
- NCT02096081
- Testing
- IncobotulinumtoxinA, OnabotulinumtoxinA
- Where
- 10 sites in United States
- Volunteers
- 250 people
- Sponsor
- Merz North America, Inc.
Glabellar Frown Lines
Safety and Efficacy Study of Dysport RU and Glabellar Lines
The primary objective is to assess the dose response versus placebo of a single treatment of Dysport RU (Dysport RU, Ready to Use, for injection), for the improvement in appearance of moderate to severe glabellar lines at maximum…
- Trial name
- NCT01333397
- Testing
- Botulinum toxin type A
- Where
- 8 sites in France, Germany
- Volunteers
- 176 people
- Sponsor
- Ipsen
Moderate-severe Glabellar Lines
Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines
Evaluate onset time and safety of improvement effect of each group's forehead wrinkles after 2, 3, 4, 5, 14 days from administration of 20U dosage of DWP450-004 for adult patients who need more than moderate improvement of…
- Trial name
- NCT02568150
- Testing
- Single group, open-label
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glabellar Frown Lines
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
This is a long term safety study of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines following single and repeat administration.
- Trial name
- NCT03004248
- Testing
- Botulinum Toxins, Type A
- Where
- 61 sites in United States, Canada
- Volunteers
- 2,691 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Frown Lines
The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines
A Phase Ⅲ Clinical Trial to Compare the Safety and Efficacy of Hutox versus Botox® in Subject with Moderate to Severe Glabellar Lines
- Trial name
- NCT03440671
- Testing
- Hutox Inj, Botox Inj
- Where
- South Korea
- Volunteers
- 260 people
- Sponsor
- Huons Co., Ltd.
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in…
- Trial name
- EV-006 (NCT02428608)
- Testing
- DWP-450 (Botulinum purified neurotoxin, Type A)
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Lines, Glabellar Frown Lines
A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines
The aim of this study is to evaluate the efficacy and safety of AbobotulinumtoxinA (produced by Espad Pharmed Darou Co.) for correction of moderate to severe glabellar lines.
- Trial name
- NCT06946160
- Testing
- Abobotulinumtoxin A (Espad Pharmed Darou Co.), Abobotulinumtoxin A (Ipsen Co.)
- Where
- Iran
- Volunteers
- 146 people
- Sponsor
- Espad Pharmed
Glabellar Frown Lines
Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines
STUDY QUESTION: Does the depth of injection of onabotulinumtoxinA neurotoxin in the glabellar complex affect efficacy of the BoTN for the improvement of glabellar frown lines? STUDY AIM Primary objective: Compare the efficacy of…
- Trial name
- NCT05766683
- Testing
- onabotulinumtoxinA at a depth of 2mm, onabotulinumtoxinA at a depth of 4mm
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Glabellar Frown Lines
Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
This study is intended to evaluate long-term safety and efficacy of MBA-P01 in treatment of glabellar lines.
- Trial name
- NCT05321979
- Testing
- MBA-P01
- Where
- South Korea
- Volunteers
- 253 people
- Sponsor
- Medytox Korea